Craft

CEL-SCI

Stock Price

$0.9

2024-10-29

Market Capitalization

$58.7 M

2024-10-29

CEL-SCI Summary

Company Summary

Overview
CEL-SCI is a biotechnology company. It is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases. The company provides Multikine, an investigational immunotherapy for treating head and neck cancer, and L.E.A.P.S. (ligand epitope antigen presentation system), a peptide epitope delivery technology for treating rheumatoid arthritis.
Type
Public
Status
Active
Founded
1983
HQ
Vienna, VA, US | view all locations
Website
https://cel-sci.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Geert R. Kersten

    Geert R. Kersten, Director and Chief Executive Officer

    • Eyal Talor

      Eyal Talor, Chief Scientific Officer

    • Patricia B. Prichep

      Patricia B. Prichep, Senior Vice President of Operations

      • Daniel Zimmerman

        Daniel Zimmerman, Senior Vice President of Cellular Immunology

      LocationsView all

      1 location detected

      • Vienna, VA HQ

        United States

        8229 Boone Blvd # 802

      CEL-SCI Financials

      Summary Financials

      Net income (Q2, 2026)
      ($5.5M)
      Cash (Q2, 2026)
      $1.9M
      EBIT (Q2, 2026)
      ($5.3M)
      Enterprise value
      $62.9M

      Footer menu